Page 65 - HPV e 100 domande
P. 65

AGMGIAORGNGAIMOE2N0T1O8:

5.27 Dove si possono trovare altre informazioni sul vaccino HPV?
â—†	Sul sito di Epicentro: http://www.epicentro.iss.it/temi/vaccinazioni/ [ultimo accesso 22

   aprile 2018]
◆	Sul sito dell’OMS: http://www.who.int/immunization/topics/hpv/en/ [ultimo accesso 22

   aprile 2018]
â—†	Sul sito del Ministero della salute: http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?

   lingua=italiano&menu=notizie&p=dalministero&id=2803 [ultimo accesso 22 aprile 2018]

BIBLIOGRAFIA SEZIONE 5
Ali H, Donovan B, Wand H et al. Genital warts in young Australians five years into nation-

   al human papillomavirus vaccination programme: national surveillance data. BMJ 2013 Apr
   18;346:f2032. doi:10.1136/bmj.f2032.
Brotherton JML, Bloem PN. Population-based HPV vaccination programmes are safe and
   effective: 2017 update and the impetus for achieving better global coverage. Best Practice
   & Research Clinical Obstetrics and Gynaecology 2017; pii:S1521-6934(17)30128-1.
Castellsagué X, Giuliano AR, Goldstone S, et al. Immunogenicity and safety of the 9-valent
   HPV vaccine in men. Vaccine 2015;33(48): 6892-901.
Castellsaguè X, Munoz N, Pitisuttithum P et al. End of study safety, immunogenity, and effi-
   cacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 25-45
   years of age. Br J Cancer 2011;105(1):28-37.
Cocchio S, Baldovin T, Bertoncello C et al. Decline in hospitalization for genital warts in the
   Veneto region after an HPV vaccination program: an observational study. BMC Infect Dis
   2017;17:249. Published online 2017 Apr 5. doi:10.1186/s12879-017-2361-5.
De Vincenzo R, Conte C, Ricci C et al. Long-term efficacy and safety of human papilloma-
   virus vaccination Int J Womens Health 2014; 6: 999–1010. Published online 2014 Dec 3.
   doi:10.2147/IJWH.S50365.
EMA 2015 European Medicine Agency. HPV vaccines: EMA confirms evidence does not sup-
   port that they cause CRPS or POTS. EMA/749763/2015. November 2015. http://www.ema.
   europa.eu/docs/en_GB/document_library/Press_release/2015/11/WC500196762.pdf [ulti-
   mo accesso 1 maggio 2018].
European Medicines Agency. Gardasil 9. http://www.ema.europa.eu/ema/index.jsp?curl=
   pages/medicines/human/medicines/003852/human_med_001863.jsp&mid=
   WC0b01ac058001d124 [ultimo accesso 1 maggio 2018].
Feiring B, Laake I, Bakken IJ, et al. HPV vaccination and risk of chronic fatigue syndrome/
   myalgic encephalomyelitis: a nationwide register-based study from Norway. Vaccine
   2017;35:4203-421.
FUTURE II Study group. Quadrivalent vaccine against human papillomavirus to prevent high-
   grade cervical lesions. N Eng J Med 2007;356:1915e-27.
Garland SM, Kjaer SK, Muñoz N et al. Impact and Effectiveness of the Quadrivalent Human
   Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin
   Infect Dis 2016;63(4):519-27. doi: https://doi.org/10.1093/cid/ciw354.
Giorgi Rossi P, Carozzi F, Federici A. Cervical cancer screening in women vaccinated against
   human infection: Recommendations from a consensus conference Prev Med 2017;98:21-
   30.

Le 100 DOMANDE sull’HPV         63
Informazioni per gli operatori
   60   61   62   63   64   65   66   67   68   69   70